Figure 2.

Overall survival (OS) from time of progression. Kaplan–Meier plot of OS by treatment status beyond progression. Inset displays median post-progression OS and 12-month OS rates. Median post-progression survival follow-up durations were 17.3 months (range, 0.2+ to 21.0 months) in patients who received atezolizumab beyond progression 15.0 months (range, 1.0+ to 16.7 months) in patients who received other systemic therapy, and not estimable (range, 0-11.5+ months) in patients who received no systemic therapy beyond progression.